English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/203100
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia

AuthorsVicente-Dueñas, Carolina ; González-Herrero, Inés ; Sehgal, Lalit; García-Ramírez, Idoia ; Rodríguez-Hernández, Guillermo ; Pintado, Belén; Blanco, Óscar; García Criado, Francisco Javier; García-Cenador, Begoña; Green, Michael R.; Sánchez García, Isidro
Issue Date2019
PublisherSpringer Nature
CitationLeukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 33: 249-278 (2019)
AbstractThe clonal nature of cancer evolution dictates that all tumor cells carry the same cancer-initiating genetic lesions. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of the tumor. Studies on different types of hematopoietic and solid tumors have shown that the contribution of some oncogenes to cancer development is mediated through the epigenetic reprogramming of the cancer-initiating target cell [1,2,3,4]. Epigenetic reprogramming is therefore a new type of interaction between oncogenes and tumor cells, in which the oncogene primes for cancer development by establishing a new pathological tumor cell identity. The current challenge is to test whether epigenetic remodeling in the absence of the driver oncogene is sufficient for tumorigenesis.
Publisher version (URL)http://dx.doi.org/10.1038/s41375-018-0192-z
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.